Drugs / β-glucan
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00911560 | May 2009 → May 2027 expected | neuroblastoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06057948 | Sep 2023 → Mar 2027 expected | neuroblastoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | β-glucan | “Participants will receive oral β-glucan (40 mg/kg/day) for 14 days on, and 14 days off” NCT06057948 ↗ |
| Modality | Other / unclassified | “β-glucan which is a kind of sugar from yeast” NCT00911560 ↗ |
| Route | Oral | “β-glucan is taken by mouth” NCT00911560 ↗ |